Navigation Links
Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial
Date:1/27/2009

SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today preliminary progression-free survival (PFS) results from its pivotal phase III EXTEND (PIX301) trial of pixantrone that show patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs. 2.6 months, p < 0.01, pixantrone vs. standard chemotherapy) based on an intent to treat analysis. PFS was a prospectively defined secondary endpoint in the study.

"We always believed the effectiveness of pixantrone would translate into a meaningful difference for patients with relapsed aggressive NHL and these dramatic and significant differences in PFS in this tough to treat group of patients provides that evidence," stated James A. Bianco, M.D. Chief Executive Officer of CTI. "Pixantrone is the first agent in this patient population to demonstrate a significant and meaningful PFS advantage. We believe these data will support a priority review designation on our New Drug Application (NDA) once we share them with the Food and Drug Administration (FDA)."

The Company had previously announced that its pivotal phase III (PIX 301) EXTEND trial had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission. Additionally, pixantrone treatment also significantly increased the overall response rate (CR/CRu+PR) (26/70 (37.1%) for pixantrone arm compared to 10/70 (
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. Demand for VScan Dengue Fever Test Kits Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... 2010 Abbott Diabetes Care today announced that it ... million strips) of Precision Xtra®, Precision Xceed Pro®, MediSense® ... Strips in the United States and Puerto Rico. ... Precision Xtra, Precision Xceed Pro, MediSense Optium, Optium and ...
... 2010 Heska Corporation (Nasdaq: HSKA ) announces ... to Its Special Meeting of Stockholders on the WebWhen: , ... (click on the Special Meeting of Stockholders link on ... Internet -- Simply log on to the web at the ...
Cached Medicine Technology:Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 2Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 3Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 4Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 5Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 6Webcast Alert: Heska Corporation's Special Meeting of Stockholders Webcast 2
(Date:4/22/2014)... are more likely to have a child who develops ... A recent study from researchers from the Drexel University ... in Sweden provides more insight into how the risk ... ages, and found that the risk of having a ... for older parents., In the study, published in the ...
(Date:4/22/2014)... Based on results of a clinical trial led ... and Drug Administration (FDA) approved a molecularly targeted ... that has progressed after standard chemotherapy has failed. ... was announced by the manufacturer, Lilly Oncology, of ... ramucirumab, it will be sold under the name ...
(Date:4/22/2014)... identify patients who are at highest risk for respiratory ... condition, suggest data from a large multi-center study published ... Affecting nearly 200,000 Americans a year, acute respiratory distress ... caused by a number of issues ranging from smoke ... develop ARDS after surgery. ARDS is difficult to treat ...
(Date:4/22/2014)... out of the University of Calgary,s Hotchkiss Brain Institute ... nerve cells as a means to restore connections after ... a key molecule that directly regulates nerve cell growth ... in the prestigious journal Nature Communications , with ... "We made the surprising discovery that a protein ...
(Date:4/21/2014)... ROCHESTER, Minn. Acute respiratory distress syndrome is ... Patients who develop the lung disorder postoperatively are ... and those who survive the syndrome may still ... A Mayo Clinic-led study is helping physicians better ... toward preventing this dangerous and costly surgical complication. ...
Breaking Medicine News(10 mins):Health News:Child's autism risk accelerates with mother's age over 30 2Health News:Child's autism risk accelerates with mother's age over 30 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:New tool helps doctors better predict, prevent deadly respiratory failure 2Health News:Scientists discover a new way to enhance nerve growth following injury 2Health News:Acute respiratory distress syndrome: Study IDs surgical patients at risk 2
... that Snake Bites are Becoming More Powerful and Patient Reactions ... marks a change in rattlesnake behavior as well. Snakes ... the rattlesnake is. In humans, a rattlesnake bite can ... the past couple of years we have seen an increase ...
... 5 Argus Health Systems, Inc., a leading provider ... Topor has been elected to the National Council for ... three-year term. The Board of Trustees oversees all Council ... development activities. Prior to the election, Topor, a 12-year ...
... support the use of lower cost sharing as an incentive ... in order to reduce costs, according to survey data published ... have been interested in bringing aspects of "consumerism" into health ... 2009 EBRI Notes , which reports the survey data. ...
... aggressive goals to expand nationwide, Wellspring ... Development. Bill will spearhead the newly formed Network Development Division ... in 2010. He is responsible for making Wellspring a household ... former Fortune 100 senior executive with healthcare, insurance and leading ...
... revenues grow by 31% and gross profit increases 85%ROCHESTER, N.Y., ... a leading provider of quantitative imaging for clinical trials, announced ... over $2.1 million, a 31% increase over prior year,s first ... was $1,119,786 compared to $604,119 in the first quarter of ...
... Advisory Board Will Host ,Day of Dialogue, Online Town Hall ... 5, 2009 America,s healthcare and long-term services need to ... of today,s seniors and people with disabilities, according to a ... The report, which will be supported by a nationwide ...
Cached Medicine News:Health News:As the Weather Warms Up Rattlesnakes Come Out to Enjoy the Sun Just as Californians Do 2Health News:New Research from EBRI: Many Support Lower Cost Sharing to Change Health Care System Use 2Health News:Wellspring Hires William Young and Prepares for Nationwide Expansion 2Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 2Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 3Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 4Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 5Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 6Health News:National Advisory Board Issues 'Declaration for Independence': A Call-to-Action in Healthcare for Seniors and People with Disabilities 2Health News:National Advisory Board Issues 'Declaration for Independence': A Call-to-Action in Healthcare for Seniors and People with Disabilities 3
PremierEdge Stab Knives - 15....
DCR Set, Straight....
... CORNEO-GAGE PLUS pachometers are acknowledged to be ... measurement-reproducible pachometers available. These benefits are due ... transducers and smallest tip footprint available coupled ... average for every displayed reading. Thus corneal ...
... Leica CM1850 cryostat for standard ... laboratory is designed for easy ... A new insulation technology used, ... refrigerating system and maintains stable ...
Medicine Products: